Hypera SA (HYPE3)

Currency in BRL
22.70
+0.64(+2.90%)
Delayed Data·
HYPE3 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.2622.81
52 wk Range
18.8628.56
Key Statistics
Bid/Ask
22.70 / 22.71
Prev. Close
22.06
Open
22.46
Day's Range
22.26-22.81
52 wk Range
18.86-28.56
Volume
566K
Average Volume (3m)
3M
1-Year Change
18.457%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HYPE3 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.69
Upside
+30.80%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Hypera SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Employees
10564
Market
Brazil

Compare HYPE3 to Peers and Sector

Metrics to compare
HYPE3
Peers
Sector
Relationship
P/E Ratio
11.7x11.8x−0.4x
PEG Ratio
−1.09−0.060.00
Price/Book
1.1x1.6x2.6x
Price / LTM Sales
1.8x2.2x3.1x
Upside (Analyst Target)
36.0%35.1%58.8%
Fair Value Upside
Unlock13.9%9.2%Unlock

Analyst Ratings

8 Buy
5 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.69
(+30.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy33.00+45.57%32.00MaintainFeb 04, 2026
UBS
Hold28.00+23.51%29.00MaintainJan 23, 2026
Scotiabank
Buy35.00+54.39%-New CoverageJul 17, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.88%
Dividend Yield
5.28%
Industry Median 2.30%
Annualized payout
1.17
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
0.71 / 0.67
Revenue / Forecast
2.24B / 2.26B
EPS Revisions
Last 90 days

HYPE3 Income Statement

People Also Watch

20.39
BRAV3
+1.24%
15.27
CPLE3
+1.66%
48.23
CPFE3
+1.20%
29.08
UGPA3
+2.61%

FAQ

What Is the Hypera (HYPE3) Stock Price Today?

The Hypera stock price today is 22.70 BRL.

What Stock Exchange Does Hypera Trade On?

Hypera is listed and trades on the B3 Stock Exchange.

What Is the Stock Symbol for Hypera?

The stock symbol for Hypera is "HYPE3."

What Is the Hypera Market Cap?

As of today, Hypera market cap is 14.36B BRL.

What Is Hypera's Earnings Per Share (TTM)?

The Hypera EPS (TTM) is 1.88.

When Is the Next Hypera Earnings Date?

Hypera will release its next earnings report on Apr 28, 2026.

From a Technical Analysis Perspective, Is HYPE3 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Hypera Stock Split?

Hypera has split 2 times.

How Many Employees Does Hypera Have?

Hypera has 10564 employees.

What is the current trading status of Hypera (HYPE3)?

As of Mar 31, 2026, Hypera (HYPE3) is trading at a price of 22.70 BRL, with a previous close of 22.06 BRL. The stock has fluctuated within a day range of 22.26 BRL to 22.81 BRL, while its 52-week range spans from 18.86 BRL to 28.56 BRL.

What Is Hypera (HYPE3) Price Target According to Analysts?

The average 12-month price target for Hypera is 29.69 BRL, with a high estimate of 35 BRL and a low estimate of 24.5 BRL. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +30.80% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.